New pill shows promise for Hard-to-Treat blood cancer in early japanese study
NCT ID NCT03985189
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new oral drug called ME-401 in 14 Japanese patients with a slow-growing form of non-Hodgkin's lymphoma that had returned or stopped responding to prior treatments. The main goals were to check the drug's safety, find the right dose, and see how the body processes it. Researchers also offered a roll-over option for continued treatment and safety monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ME-401 (a PI3K inhibitor taken orally)
What this could lead to
If successful, this could lead to a new treatment option for Japanese patients with a type of blood cancer that has come back or not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 14 participants, focused on safety and dosing. It is not designed to prove effectiveness, and the drug may cause side effects or fail in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aomori Prefectural Central Hospital
Aomori, 030-8553, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-0814, Japan
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, 466-8650, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
-
Okayama University Hospital
Okayama, 700-8558, Japan
-
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, 113-8677, Japan